Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational combination therapy is being developed by Mackay Memorial Hospital in Taiwan for the eradication of Helicobacter pylori infection. The treatment approach involves intraluminal therapy (ILTHPI), where a medicament containing the antibiotics amoxicillin and clarithromycin (sometimes in combination with metronidazole) is applied locally to the gastric mucosa during an endoscopic examination. Amoxicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. This localized, single-dose delivery method is being evaluated in Phase 4 clinical trials as a strategy to improve eradication rates and overcome compliance issues associated with traditional multi-day oral antibiotic regimens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amoxicillin + clarithromycin (Mackay Memorial Hospital).